MARK2 and amyotrophic lateral sclerosis: Given the BBB dysfunction that is confirmed for ALS, targeting PAR1 on BMECs may have additional significant therapeutic value, for example in TBI, given thrombin’s role in increasing barrier permeability by activating BBB/BMEC PAR1 [132].